About I-MAB American Depositary Shares
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Market Cap
$0.07B
Employees
220
Listed Since
January 17, 2020
Website
www.i-mabbiopharma.comCIK
0001778016